Alerts will be sent to your verified email
Verify Email
SHILPAMED
|
Shilpa Medicare
|
Aarti Pharmalabs
|
Supriya Lifescience
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceutical Sector
|
|||
|
Number of ANDA's Filed in USA
|
30.0 . | n/a | n/a |
|
Number of ANDA's Approved By USFDA
|
17.0 . | n/a | n/a |
|
Number of ANDA's Filed in Europe
|
81.0 | n/a | n/a |
|
US DMF Filings
|
48.0 . | n/a | n/a |
|
R&D as a % of Total Sales
|
3.76 % | n/a | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
5.0 % | 9.05 % | 23.4 % |
|
5yr average Equity Multiplier
|
1.64 | 1.39 | 1.25 |
|
5yr Average Asset Turnover Ratio
|
0.39 | 0.58 | 0.68 |
|
5yr Avg Net Profit Margin
|
7.72 % | 8.95 % | 25.52 % |
|
Price to Book
|
3.4 | 4.24 | 5.87 |
|
P/E
|
72.69 | 31.65 | 32.85 |
|
5yr Avg Cash Conversion Cycle
|
76.54 Days | 94.46 Days | -10.96 Days |
|
Inventory Days
|
105.79 Days | 94.9 Days | 56.1 Days |
|
Days Receivable
|
113.53 Days | 94.46 Days | 57.43 Days |
|
Days Payable
|
120.58 Days | 76.47 Days | 113.66 Days |
|
5yr Average Interest Coverage Ratio
|
11.52 | 12.05 | 60.74 |
|
5yr Avg ROCE
|
6.65 % | 12.13 % | 30.51 % |
|
5yr Avg Operating Profit Margin
|
17.76 % | 15.5 % | 36.15 % |
|
5 yr average Debt to Equity
|
0.44 | 0.16 | 0.06 |
|
5yr CAGR Net Profit
|
-27.23 % | n/a | 8.75 % |
|
5yr Average Return on Assets
|
3.1 % | 6.11 % | 17.81 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
44.23 % | 43.72 % | 68.3 % |
|
Share Pledged by Promoters
|
7.92 % | 0.01 % | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-5.78 % | -2.26 % | 0.06 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
3.04 % | -4.21 % | -2.44 % |
|
Shilpa Medicare
|
Aarti Pharmalabs
|
Supriya Lifescience
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|